Ann De Blieck

Title: Innovations of Ann De Blieck

Introduction

Ann De Blieck is a notable inventor based in Sinaai, Belgium. She has made significant contributions to the field of pharmacology, particularly in the development of therapeutic agents for treating central nervous system disorders. With a total of two patents to her name, her work focuses on nicotinic acetylcholine receptor modulators.

Latest Patents

Her latest patents include the invention of 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives, which are useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders. This invention provides 2-azabicyclo[3.1.1]heptyl derivatives and methods for producing them, which serve as therapeutic agents for preventing or treating central nervous system disorders such as Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, dementia, pain, and nicotine addiction. Another significant patent involves substituted 7-azabicyclo[2.2.1]heptyl derivatives, which are useful for making pharmaceutical compositions. This invention provides 1-substituted-7-azabicyclo[2.2.1]heptyl derivatives, intermediates, and methods for producing them, aimed at the prevention and treatment of similar central nervous system disorders.

Career Highlights

Throughout her career, Ann De Blieck has worked with esteemed organizations such as Universiteit Gent and Galapagos NV. Her research and innovations have contributed to advancements in the understanding and treatment of neurologic conditions.

Collaborations

Some of her notable coworkers include Christian Stevens and Thomas Heugebaert, who have collaborated with her on various projects.

Conclusion

Ann De Blieck's contributions to the field of pharmacology through her innovative patents highlight her role as a significant inventor in the treatment of central nervous system disorders. Her work continues to pave the way for new therapeutic approaches.